首页 > 最新文献

Minerva cardioangiologica最新文献

英文 中文
Robotic-assisted coronary artery bypass grafting: current knowledge and future perspectives. 机器人辅助冠状动脉旁路移植术:目前的知识和未来的展望。
Q3 Medicine Pub Date : 2020-10-01 DOI: 10.23736/S0026-4725.20.05302-5
Andrea Amabile, Gianluca Torregrossa, Husam H Balkhy

Minimally invasive direct coronary artery bypass grafting (MIDCAB) and totally endoscopic coronary artery bypass grafting (TECAB) are the two existing strategies for robotic-assisted, surgical myocardial revascularization. In this review, we summarize the wide evidence available in the literature regarding the benefits of these two procedures, and detail the technical skills required to master robotic coronary surgery techniques.

微创直接冠状动脉旁路移植术(MIDCAB)和完全内窥镜冠状动脉旁路移植术(TECAB)是机器人辅助手术心肌血运重建术的两种现有策略。在这篇综述中,我们总结了文献中关于这两种手术的益处的广泛证据,并详细介绍了掌握机器人冠状动脉手术技术所需的技术技能。
{"title":"Robotic-assisted coronary artery bypass grafting: current knowledge and future perspectives.","authors":"Andrea Amabile,&nbsp;Gianluca Torregrossa,&nbsp;Husam H Balkhy","doi":"10.23736/S0026-4725.20.05302-5","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05302-5","url":null,"abstract":"<p><p>Minimally invasive direct coronary artery bypass grafting (MIDCAB) and totally endoscopic coronary artery bypass grafting (TECAB) are the two existing strategies for robotic-assisted, surgical myocardial revascularization. In this review, we summarize the wide evidence available in the literature regarding the benefits of these two procedures, and detail the technical skills required to master robotic coronary surgery techniques.</p>","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"68 5","pages":"497-510"},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38573434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Early versus late tracheal intubation in COVID-19 patients: a pro-con debate also considering heart-lung interactions. COVID-19患者早期与晚期气管插管:一场考虑心肺相互作用的正反辩论。
Q3 Medicine Pub Date : 2020-10-01 DOI: 10.23736/S0026-4725.20.05356-6
L. Cabrini, L. Ghislanzoni, P. Severgnini, G. Landoni, M. Baiardo Redaelli, F. Franchi, S. Romagnoli
The best timing of orotracheal intubation and invasive ventilation in COVID-19 patients with acute respiratory distress syndrome is unknown. The use of non-invasive ventilation, a life-saving technique in many medical conditions, is debated in patients with ARDS since prolonged NIV and delayed intubation may be harmful. Shortage of intensive care beds and ventilators during a respiratory pandemic can trigger a widespread use of early non-invasive ventilation in many hospitals but which is the best way to ventilate patients with severe bilateral pneumonia and severely increased spontaneous ventilation is controversial. Moreover, viral spreading to health-care workers and other hospitalized patients is an issue for any device used to administer oxygen. Even if protective mechanical ventilation is currently the gold standard for the management of acute respiratory distress syndrome, tracheal intubation is not without risks and is associated with delirium, hemodynamic instability, immobilization and post intensive care syndrome. Both invasive and non-invasive ventilation are associated with advantages and limitations that should be carefully considered when patients with COVID-19-ARDS need our attention. In the absence of strong evidence , in this review we highlight all the pro and con of these two different approaches.
COVID-19合并急性呼吸窘迫综合征患者气管插管和有创通气的最佳时机尚不清楚。在许多医疗条件下,无创通气是一种挽救生命的技术,但由于延长无创通气时间和延迟插管可能有害,因此在ARDS患者中使用无创通气存在争议。在呼吸道大流行期间,重症监护病床和呼吸机的短缺可能导致许多医院广泛使用早期无创通气,但对于严重双侧肺炎和严重自发通气增加的患者,哪种是最佳通气方式存在争议。此外,对于任何用于供氧的设备来说,病毒传播给医护人员和其他住院病人都是一个问题。即使保护性机械通气是目前管理急性呼吸窘迫综合征的金标准,气管插管也不是没有风险,并且与谵妄、血流动力学不稳定、固定和重症监护后综合征有关。有创通气和无创通气都有其优点和局限性,当COVID-19-ARDS患者需要我们关注时,应仔细考虑这些优点和局限性。在缺乏有力证据的情况下,我们在这篇综述中强调了这两种不同方法的所有优点和缺点。
{"title":"Early versus late tracheal intubation in COVID-19 patients: a pro-con debate also considering heart-lung interactions.","authors":"L. Cabrini, L. Ghislanzoni, P. Severgnini, G. Landoni, M. Baiardo Redaelli, F. Franchi, S. Romagnoli","doi":"10.23736/S0026-4725.20.05356-6","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05356-6","url":null,"abstract":"The best timing of orotracheal intubation and invasive ventilation in COVID-19 patients with acute respiratory distress syndrome is unknown. The use of non-invasive ventilation, a life-saving technique in many medical conditions, is debated in patients with ARDS since prolonged NIV and delayed intubation may be harmful. Shortage of intensive care beds and ventilators during a respiratory pandemic can trigger a widespread use of early non-invasive ventilation in many hospitals but which is the best way to ventilate patients with severe bilateral pneumonia and severely increased spontaneous ventilation is controversial. Moreover, viral spreading to health-care workers and other hospitalized patients is an issue for any device used to administer oxygen. Even if protective mechanical ventilation is currently the gold standard for the management of acute respiratory distress syndrome, tracheal intubation is not without risks and is associated with delirium, hemodynamic instability, immobilization and post intensive care syndrome. Both invasive and non-invasive ventilation are associated with advantages and limitations that should be carefully considered when patients with COVID-19-ARDS need our attention. In the absence of strong evidence , in this review we highlight all the pro and con of these two different approaches.","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85757095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 25
Marijuana influence on cardiac modulation and heart rate: novel hypotheses and gaps in evidence. 大麻对心脏调节和心率的影响:新的假设和证据的空白。
Q3 Medicine Pub Date : 2020-10-01 DOI: 10.23736/S0026-4725.20.05497-3
G. Iannaccone, I. Porto
{"title":"Marijuana influence on cardiac modulation and heart rate: novel hypotheses and gaps in evidence.","authors":"G. Iannaccone, I. Porto","doi":"10.23736/S0026-4725.20.05497-3","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05497-3","url":null,"abstract":"","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88546856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Correlation of heart rate and blood pressure variability as well as hs-CRP with the burden of stable coronary artery disease. 心率、血压变异性及hs-CRP与稳定型冠状动脉疾病负担的相关性
Q3 Medicine Pub Date : 2020-10-01 Epub Date: 2020-04-23 DOI: 10.23736/S0026-4725.20.05153-1
Xiong Peng, Dingfeng Peng, Yongjun Hu, Hongsheng Gang, Yijun Yu, Shaoyong Tang

Background: The aim is to investigate the predictive value of heart rate variability (HRV), blood pressure variability (BPV), and high-sensitivity C-reactive protein (hs-CRP) levels in patients with stable coronary artery disease (SCAD) to assess whether these variables predict the Gensini score.

Methods: Five hundred and eighty-eight patients with SCAD were enrolled. Normal coronary angiography (102 patients) and healthy physical examination patients (104 patients) were enrolled as control group for HRV. Dynamic electrocardiogram, ambulatory blood pressure, and hs-CRP were measured in SCHD, and Gensini scores were calculated. The relationship between the level of Gensini scores and HRV, BPV and hs-CRP in SCAD was analyzed. We assessed the predictive value of non-invasive markers for the degree of coronary artery disease in SCAD.

Results: HRV was negatively correlated with coronary lesions Gensini scores, and BPV was positively correlated with them. The correlation coefficients of SDNN, PNN50, SDANN, RMSSD, and TRIA in HRV are -0.327, -0.489, -0.153 -0.206, -0.292, respectively (P<0.01); while 24hSBPV, 24hDBPV, dSBPV, dDBPV, nSBPV and nSBPdrinBPV were 0.286, 0.233, 0.141, 0.139, 0.218, 0.113, respectively (P<0.01). hs-CRP was positively correlated with the Gensini scores of coronary lesions (0.325, P<0.01), HRV decreased (PNN50<14.97, TRIA<160.86) and BPV increased (24hSBPV>20%, nSBPV>20%) combined with hs-CRP positive (hs-CR >3.0 mg/L) performance can effectively predict coronary lesions in SCAD.

Conclusions: HRV, BPV and hs-CRP are all significantly associated with coronary lesions. And these variables can predict the Gensini score in SCAD.

背景:目的是研究心率变异性(HRV)、血压变异性(BPV)和高敏c反应蛋白(hs-CRP)水平在稳定型冠状动脉疾病(SCAD)患者中的预测价值,以评估这些变量是否能预测Gensini评分。方法:纳入588例SCAD患者。选取冠状动脉造影正常(102例)和体检健康(104例)作为HRV对照组。测定动态心电图、动态血压、hs-CRP,计算Gensini评分。分析SCAD患者Gensini评分水平与HRV、BPV、hs-CRP的关系。我们评估了非侵入性标志物对SCAD患者冠状动脉病变程度的预测价值。结果:HRV与冠状动脉病变Gensini评分呈负相关,BPV与冠状动脉病变Gensini评分呈正相关。SDNN、PNN50、SDANN、RMSSD、TRIA在HRV中的相关系数分别为-0.327、-0.489、-0.153、-0.206、-0.292 (P20%, nSBPV>20%),结合hs-CRP阳性(hs-CR >3.0 mg/L)表现可有效预测SCAD患者冠状动脉病变。结论:HRV、BPV、hs-CRP与冠状动脉病变均有显著相关性。这些变量可以预测SCAD的Gensini评分。
{"title":"Correlation of heart rate and blood pressure variability as well as hs-CRP with the burden of stable coronary artery disease.","authors":"Xiong Peng,&nbsp;Dingfeng Peng,&nbsp;Yongjun Hu,&nbsp;Hongsheng Gang,&nbsp;Yijun Yu,&nbsp;Shaoyong Tang","doi":"10.23736/S0026-4725.20.05153-1","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05153-1","url":null,"abstract":"<p><strong>Background: </strong>The aim is to investigate the predictive value of heart rate variability (HRV), blood pressure variability (BPV), and high-sensitivity C-reactive protein (hs-CRP) levels in patients with stable coronary artery disease (SCAD) to assess whether these variables predict the Gensini score.</p><p><strong>Methods: </strong>Five hundred and eighty-eight patients with SCAD were enrolled. Normal coronary angiography (102 patients) and healthy physical examination patients (104 patients) were enrolled as control group for HRV. Dynamic electrocardiogram, ambulatory blood pressure, and hs-CRP were measured in SCHD, and Gensini scores were calculated. The relationship between the level of Gensini scores and HRV, BPV and hs-CRP in SCAD was analyzed. We assessed the predictive value of non-invasive markers for the degree of coronary artery disease in SCAD.</p><p><strong>Results: </strong>HRV was negatively correlated with coronary lesions Gensini scores, and BPV was positively correlated with them. The correlation coefficients of SDNN, PNN50, SDANN, RMSSD, and TRIA in HRV are -0.327, -0.489, -0.153 -0.206, -0.292, respectively (P<0.01); while 24hSBPV, 24hDBPV, dSBPV, dDBPV, nSBPV and nSBPdrinBPV were 0.286, 0.233, 0.141, 0.139, 0.218, 0.113, respectively (P<0.01). hs-CRP was positively correlated with the Gensini scores of coronary lesions (0.325, P<0.01), HRV decreased (PNN50<14.97, TRIA<160.86) and BPV increased (24hSBPV>20%, nSBPV>20%) combined with hs-CRP positive (hs-CR >3.0 mg/L) performance can effectively predict coronary lesions in SCAD.</p><p><strong>Conclusions: </strong>HRV, BPV and hs-CRP are all significantly associated with coronary lesions. And these variables can predict the Gensini score in SCAD.</p>","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"68 5","pages":"376-382"},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37865399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Extracorporeal membrane oxygenation for COVID-19: effective weapon or futile effort? 体外膜氧合治疗COVID-19:有效武器还是徒劳?
Q3 Medicine Pub Date : 2020-10-01 DOI: 10.23736/S0026-4725.20.05377-3
Natalia Pavone, Francesco Burzotta, Massimo Massetti
{"title":"Extracorporeal membrane oxygenation for COVID-19: effective weapon or futile effort?","authors":"Natalia Pavone,&nbsp;Francesco Burzotta,&nbsp;Massimo Massetti","doi":"10.23736/S0026-4725.20.05377-3","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05377-3","url":null,"abstract":"","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"68 5","pages":"365-367"},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38573435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Implantable loop recorder for syncope: essential tool or double-edged weapon? 用于晕厥的植入式循环记录仪:必备工具还是双刃剑?
Q3 Medicine Pub Date : 2020-10-01 DOI: 10.23736/S0026-4725.20.05498-5
E. Ebrille, P. Crea
{"title":"Implantable loop recorder for syncope: essential tool or double-edged weapon?","authors":"E. Ebrille, P. Crea","doi":"10.23736/S0026-4725.20.05498-5","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05498-5","url":null,"abstract":"","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88342028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual antiplatelet therapy duration after percutaneous coronary intervention with drug-eluting stents: how short can we go? 经皮冠状动脉介入治疗药物洗脱支架后的双重抗血小板治疗时间:我们能持续多久?
Q3 Medicine Pub Date : 2020-10-01 Epub Date: 2020-09-29 DOI: 10.23736/S0026-4725.20.05196-8
Fausto Roccasalva, Giuseppe Ferrante

Current guidelines recommend a duration of dual antiplatelet therapy (DAPT) with aspirin and oral P2Y12 receptor inhibitors following percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) of 6 months for most patients with stable coronary disease and of 12 months for most patients with acute coronary syndromes. Large evidence from randomised clinical trials of shorter DAPT regimens after PCI with newer-generation DES is now emerging in heterogenous patient population not selected on the basis of high bleeding risk as well as in patients at high bleeding risk. The scope of this review is to provide an update on the benefits and harms of these short DAPT regimens and to discuss future directions in DAPT strategies after PCI with newer generation DES.

目前的指南建议,对于大多数稳定型冠状动脉疾病患者,经皮冠状动脉介入治疗(PCI)和第二代药物洗脱支架(DES)后,阿司匹林和口服P2Y12受体抑制剂的双重抗血小板治疗(DAPT)持续时间为6个月,对于大多数急性冠状动脉综合征患者,持续时间为12个月。来自随机临床试验的大量证据表明,在PCI术后使用新一代DES的较短DAPT方案,现在出现在非基于高出血风险选择的异质患者人群中,以及在高出血风险患者中。本综述的范围是提供这些短期DAPT方案的益处和危害的最新情况,并讨论采用新一代DES的PCI后DAPT策略的未来方向。
{"title":"Dual antiplatelet therapy duration after percutaneous coronary intervention with drug-eluting stents: how short can we go?","authors":"Fausto Roccasalva,&nbsp;Giuseppe Ferrante","doi":"10.23736/S0026-4725.20.05196-8","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05196-8","url":null,"abstract":"<p><p>Current guidelines recommend a duration of dual antiplatelet therapy (DAPT) with aspirin and oral P2Y<inf>12</inf> receptor inhibitors following percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) of 6 months for most patients with stable coronary disease and of 12 months for most patients with acute coronary syndromes. Large evidence from randomised clinical trials of shorter DAPT regimens after PCI with newer-generation DES is now emerging in heterogenous patient population not selected on the basis of high bleeding risk as well as in patients at high bleeding risk. The scope of this review is to provide an update on the benefits and harms of these short DAPT regimens and to discuss future directions in DAPT strategies after PCI with newer generation DES.</p>","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"68 5","pages":"436-450"},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38431249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Left main coronary artery disease: when and how to perform PCI? 左主干冠状动脉疾病:何时及如何行PCI?
Q3 Medicine Pub Date : 2020-10-01 Epub Date: 2020-02-26 DOI: 10.23736/S0026-4725.20.05198-1
Mauro Chiarito, Julinda Mehilli

Left main coronary artery (LMCA) disease has been reported in up to 10% of all patients with coronary artery disease (CAD) and in the majority of cases are associated with severe three-vessel CAD. Among patients with chronic coronary syndrome revascularization of significant LMCA disease improves prognosis, while there is a debate about which revascularization strategy, CABG surgery or percutaneous coronary interventions to use. We do a review of the available evidence about the impact of LMCA lesions on patient prognosis according to CAD extension and clinical presentation, the outcome after percutaneous or surgical revascularization, the procedural challenges of LMCA PCI and the available armamentarium to optimally treat this relevant population.

据报道,高达10%的冠状动脉疾病(CAD)患者存在左主干冠状动脉(LMCA)病变,并且大多数病例与严重的三支血管冠心病相关。在慢性冠状动脉综合征患者中,严重LMCA疾病的血运重建术可改善预后,但对于采用何种血运重建术策略,CABG手术还是经皮冠状动脉介入治疗存在争议。我们根据CAD的扩展和临床表现,经皮或手术血运重建术后的结果,LMCA PCI的程序挑战以及可用的设备来最佳治疗相关人群,对LMCA病变对患者预后的影响进行了回顾。
{"title":"Left main coronary artery disease: when and how to perform PCI?","authors":"Mauro Chiarito,&nbsp;Julinda Mehilli","doi":"10.23736/S0026-4725.20.05198-1","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05198-1","url":null,"abstract":"<p><p>Left main coronary artery (LMCA) disease has been reported in up to 10% of all patients with coronary artery disease (CAD) and in the majority of cases are associated with severe three-vessel CAD. Among patients with chronic coronary syndrome revascularization of significant LMCA disease improves prognosis, while there is a debate about which revascularization strategy, CABG surgery or percutaneous coronary interventions to use. We do a review of the available evidence about the impact of LMCA lesions on patient prognosis according to CAD extension and clinical presentation, the outcome after percutaneous or surgical revascularization, the procedural challenges of LMCA PCI and the available armamentarium to optimally treat this relevant population.</p>","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"68 5","pages":"405-414"},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37685728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Further advancement in the percutaneous revascularization of coronary chronic total occlusions: the redefined "Minimalistic Hybrid Approach" algorithm. 冠状动脉慢性全闭塞经皮血管重建术的进一步进展:重新定义的“极简混合入路”算法。
Q3 Medicine Pub Date : 2020-10-01 DOI: 10.23736/S0026-4725.20.05381-5
G. Vescovo, C. Zivelonghi, B. Scott, P. Agostoni
A careful angiographic assessment of a chronic total occlusion (CTO) is essential for optimal procedural planning. In the classic Hybrid Approach, the insertion of two guiding catheters at the beginning of the intervention is recommended. This is fundamental to perform simultaneous double injection, to achieve complete visualization of the coronary circulation and to choose the best starting strategy between antegrade wire escalation (AWE), antegrade dissection and re-entry (ADR) and the retrograde techniques (retrograde wire escalation [RWE] and retrograde dissection and re-entry [RDR]). In the Hybrid Algorithm the set-up is the same, regardless of the chosen first strategy, and therefore routinely uses double access. Because revascularizations of CTOs commonly require large bore catheters (7-8 French) to ensure high back up support, the femoral arterial access is preferred by most of the operators. However, the use of a double access, large introducer sheaths and femoral approach are associated with a greater risk of access-related complications and even the occurrence of major adverse cardiovascular events. We have previously proposed an algorithm, called "Minimalistic Hybrid Approach", which aims to limit the routine use of dual injection, and to favour the use of trans-radial access and smaller (6-7 French) guiding catheters. In this algorithm the chosen starting strategy depends on the complexity of the lesion assessed by J-CTO score and on the presence of favourable contralateral interventional collateral circulation. However, this novel algorithm proved to have some limitations, such as the non-specific evaluation of CTOs with ipsilateral collateral circulation and the too arbitrary choice of the starting strategy based on a J-CTO score cut-off. These considerations led to the development of an "updated" Minimalistic Hybrid Approach algorithm that takes into account the type of collaterals (ipsilateral or contralateral) and the "a priori" choice of the hybrid technique, with the highest chance of success in that specific CTO lesion (independently from the J-CTO score). One important aspect that makes this algorithm unique is its "dynamicity": not only for the technique to be used, as in the classic hybrid algorithm (shifting between AWE, ADR, RWE and RDR), but also for the set-up, with access site and French size to be adapted during the PCI to the technique adopted. We believe that this novel approach could further improve the safety of CTO-PCI without losing its current efficacy.
仔细的血管造影评估慢性全闭塞(CTO)是必要的最佳程序规划。在经典的混合入路中,建议在介入治疗开始时插入两根导尿管。这是同时进行双重注射的基础,以实现冠状动脉循环的完整可视化,并在顺行钢丝扩张术(AWE)、顺行夹层再入术(ADR)和逆行技术(逆行钢丝扩张术(RWE)和逆行夹层再入术(RDR))之间选择最佳起始策略。在混合算法中,设置是相同的,无论选择第一个策略,因此通常使用双重访问。由于cto的血运重建术通常需要大口径导管(7-8 French)以确保高支撑,因此大多数手术人员首选股动脉通道。然而,使用双通道、大导管鞘和股骨入路与通道相关并发症的风险更高,甚至发生主要不良心血管事件。我们之前提出了一种算法,称为“极简混合方法”,其目的是限制常规双重注射的使用,并倾向于使用跨径向通道和更小的(6-7 French)引导导管。在该算法中,选择的起始策略取决于由J-CTO评分评估的病变的复杂性以及是否存在有利的对侧介入侧支循环。然而,该算法存在一定的局限性,如对具有同侧侧支循环的cto进行非特异性评价,以及基于J-CTO评分截止点的起始策略选择过于随意。这些考虑导致了一种“更新”的最小化混合方法算法的发展,该算法考虑了侧枝的类型(同侧或对侧)和混合技术的“先验”选择,在特定的CTO病变中成功率最高(独立于J-CTO评分)。使该算法独特的一个重要方面是它的“动态性”:不仅适用于使用的技术,如经典的混合算法(在AWE, ADR, RWE和RDR之间切换),而且适用于设置,在PCI期间可根据所采用的技术调整访问站点和法国大小。我们相信这种新方法可以进一步提高CTO-PCI的安全性,而不会失去其目前的疗效。
{"title":"Further advancement in the percutaneous revascularization of coronary chronic total occlusions: the redefined \"Minimalistic Hybrid Approach\" algorithm.","authors":"G. Vescovo, C. Zivelonghi, B. Scott, P. Agostoni","doi":"10.23736/S0026-4725.20.05381-5","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05381-5","url":null,"abstract":"A careful angiographic assessment of a chronic total occlusion (CTO) is essential for optimal procedural planning. In the classic Hybrid Approach, the insertion of two guiding catheters at the beginning of the intervention is recommended. This is fundamental to perform simultaneous double injection, to achieve complete visualization of the coronary circulation and to choose the best starting strategy between antegrade wire escalation (AWE), antegrade dissection and re-entry (ADR) and the retrograde techniques (retrograde wire escalation [RWE] and retrograde dissection and re-entry [RDR]). In the Hybrid Algorithm the set-up is the same, regardless of the chosen first strategy, and therefore routinely uses double access. Because revascularizations of CTOs commonly require large bore catheters (7-8 French) to ensure high back up support, the femoral arterial access is preferred by most of the operators. However, the use of a double access, large introducer sheaths and femoral approach are associated with a greater risk of access-related complications and even the occurrence of major adverse cardiovascular events. We have previously proposed an algorithm, called \"Minimalistic Hybrid Approach\", which aims to limit the routine use of dual injection, and to favour the use of trans-radial access and smaller (6-7 French) guiding catheters. In this algorithm the chosen starting strategy depends on the complexity of the lesion assessed by J-CTO score and on the presence of favourable contralateral interventional collateral circulation. However, this novel algorithm proved to have some limitations, such as the non-specific evaluation of CTOs with ipsilateral collateral circulation and the too arbitrary choice of the starting strategy based on a J-CTO score cut-off. These considerations led to the development of an \"updated\" Minimalistic Hybrid Approach algorithm that takes into account the type of collaterals (ipsilateral or contralateral) and the \"a priori\" choice of the hybrid technique, with the highest chance of success in that specific CTO lesion (independently from the J-CTO score). One important aspect that makes this algorithm unique is its \"dynamicity\": not only for the technique to be used, as in the classic hybrid algorithm (shifting between AWE, ADR, RWE and RDR), but also for the set-up, with access site and French size to be adapted during the PCI to the technique adopted. We believe that this novel approach could further improve the safety of CTO-PCI without losing its current efficacy.","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"97 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72958912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Long-term prognostic potential of microRNA-150-5p in optimally treated heart failure patients with reduced ejection fraction. A pilot study. microRNA-150-5p在最佳治疗的心力衰竭患者的长期预后潜力。一项初步研究。
Q3 Medicine Pub Date : 2020-10-01 DOI: 10.23736/S0026-4725.20.05366-9
D. Scrutinio, F. Conserva, P. Guida, A. Passantino
BACKGROUNDIn a previous study, we found that miR-150-5p was specifically downregulated in patients with advanced heart failure (HF). Here, we investigated the long-term prognostic potential of miR-150-5p.METHODSWe studied optimally treated HF outpatients with reduced ejection fraction. The primary outcome comprised the composite of death, urgent heart transplantation (HT) and ventricular assist device (VAD) implantation within 30 months. We used recursive partitioning analysis to identify the optimal log miR-150-5p cut-off. The association of log miR-150-5p with the primary outcome was examined using Cox regression analysis. We used the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score for adjustment in multivariable analysis. Finally, we compared the global fit of three models (MAGGIC score+miR-150-5p, MAGGIC score+NT-proBNP, and NT-proBNP+miR-150-5p) using Akaike Information Criterion.RESULTSRecursive partitioning analysis identified the value of -2.22 as the optimal cut-off for log miR-150-5p. Thirty-month survival free of urgent HT/VAD implantation was 31% among the patients with log miR-150-5p <-2.22 and 86% among those with log miR-150-5p >-2.22. Crude hazard ratio (HR) of the primary outcome for log miR-150-5p expression level < -2.22 was 6.70 (95%CI:2.31-19.38;p<.001). After adjusting for the MAGGIC score in multivariable analysis, the HR was 4.40 (95%CI:1.52-12.77;p=.006). Adding log miR-150-5p to the MAGGIC score led to an increase of 0.047 in C-index. The model combining miR-150-5p and MAGGIC score had a 73% likelihood of representing the best-fit model of those evaluated.CONCLUSIONSOur data generate the hypothesis that miR-150-5p may represent a novel risk marker in HF with reduced ejection fraction.
在之前的一项研究中,我们发现miR-150-5p在晚期心力衰竭(HF)患者中特异性下调。在这里,我们研究了miR-150-5p的长期预后潜力。方法我们研究了最佳治疗的心衰门诊患者射血分数降低。主要结局包括30个月内死亡、紧急心脏移植(HT)和心室辅助装置(VAD)植入。我们使用递归划分分析来确定最优日志miR-150-5p截止值。使用Cox回归分析检验log miR-150-5p与主要结局的相关性。我们使用meta分析全球慢性心力衰竭(MAGGIC)风险评分对多变量分析进行调整。最后,我们使用Akaike信息标准比较了三种模型(MAGGIC评分+miR-150-5p, MAGGIC评分+NT-proBNP和NT-proBNP+miR-150-5p)的整体拟合。结果递归划分分析确定-2.22为log miR-150-5p的最佳截止值。在log miR-150-5p -2.22的患者中,无紧急HT/VAD植入的30个月生存率为31%。log miR-150-5p表达水平< -2.22时,主要结局的粗风险比(HR)为6.70 (95%CI:2.31-19.38;p<.001)。在多变量分析中调整MAGGIC评分后,风险比为4.40 (95%CI:1.52-12.77;p= 0.006)。在MAGGIC评分中加入log miR-150-5p, C-index升高0.047。结合miR-150-5p和MAGGIC评分的模型有73%的可能性代表被评估者的最佳拟合模型。我们的数据提出了这样的假设:miR-150-5p可能是射血分数降低的心衰患者中一种新的风险标志物。
{"title":"Long-term prognostic potential of microRNA-150-5p in optimally treated heart failure patients with reduced ejection fraction. A pilot study.","authors":"D. Scrutinio, F. Conserva, P. Guida, A. Passantino","doi":"10.23736/S0026-4725.20.05366-9","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05366-9","url":null,"abstract":"BACKGROUND\u0000In a previous study, we found that miR-150-5p was specifically downregulated in patients with advanced heart failure (HF). Here, we investigated the long-term prognostic potential of miR-150-5p.\u0000\u0000\u0000METHODS\u0000We studied optimally treated HF outpatients with reduced ejection fraction. The primary outcome comprised the composite of death, urgent heart transplantation (HT) and ventricular assist device (VAD) implantation within 30 months. We used recursive partitioning analysis to identify the optimal log miR-150-5p cut-off. The association of log miR-150-5p with the primary outcome was examined using Cox regression analysis. We used the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score for adjustment in multivariable analysis. Finally, we compared the global fit of three models (MAGGIC score+miR-150-5p, MAGGIC score+NT-proBNP, and NT-proBNP+miR-150-5p) using Akaike Information Criterion.\u0000\u0000\u0000RESULTS\u0000Recursive partitioning analysis identified the value of -2.22 as the optimal cut-off for log miR-150-5p. Thirty-month survival free of urgent HT/VAD implantation was 31% among the patients with log miR-150-5p <-2.22 and 86% among those with log miR-150-5p >-2.22. Crude hazard ratio (HR) of the primary outcome for log miR-150-5p expression level < -2.22 was 6.70 (95%CI:2.31-19.38;p<.001). After adjusting for the MAGGIC score in multivariable analysis, the HR was 4.40 (95%CI:1.52-12.77;p=.006). Adding log miR-150-5p to the MAGGIC score led to an increase of 0.047 in C-index. The model combining miR-150-5p and MAGGIC score had a 73% likelihood of representing the best-fit model of those evaluated.\u0000\u0000\u0000CONCLUSIONS\u0000Our data generate the hypothesis that miR-150-5p may represent a novel risk marker in HF with reduced ejection fraction.","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78832998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Minerva cardioangiologica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1